Clinical Trials Logo

Chordoma clinical trials

View clinical trials related to Chordoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06463262 Not yet recruiting - Chordoma of Sacrum Clinical Trials

Exploration of Personalized Biomarkers During Neoadjuvant Radiation Therapy for Spinal and Sacral Chordoma

Canon
Start date: July 2024
Phase:
Study type: Observational

In this study the investigators will study the effects of neoadjuvant radiation therapy (RT), in the form of either proton therapy or stereotactic body radiation therapy (SBRT), on the Circulating tumor DNA (ctDNA), radiographic changes and radiomics, and the validity of these findings will be compared using the current gold standard- pathologic findings. The purpose of this work is to explore whether the biomarkers may be used diagnostically to better understand radiographic changes following RT. The investigators hypothesize that ctDNA levels in combination with imaging biomarkers identified through radiomics will be a sensitive and specific tool for predicting histopathologic response to RT.

NCT ID: NCT05519917 Not yet recruiting - Chordoma of Clivus Clinical Trials

Study to Evaluate the Efficacy of Afatinib in Skull Base Chordoma

Start date: October 1, 2022
Phase: Phase 2
Study type: Interventional

This is a single arm, open label, single center, and prospective, interventional study to explore clinical efficacy of afatinib in patients with chordoma of skull base. Subject meeting the inclusion criteria will take afatinib (40 mg daily) orally, 4 weeks for a cycle. The primary objective is to assess the efficacy of afatinib in chordoma of skull base by objective response rate (ORR). The Secondary objectives is to assess progression free survival (PFS), overall survival (OS), tumor response duration and tumor shrinkage degree in patients with chordoma of skull base after using afatinib; to evaluate the safety and tolerability of afatinib in patients with chordoma of skull base.